Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02614508
Title Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Emory University

chronic lymphocytic leukemia/small lymphocytic lymphoma


Buparlisib + Ibrutinib

Buparlisib + Ofatumumab

Age Groups: adult
Covered Countries USA

No variant requirements are available.